Background: Candida species are the third most common cause of pediatric health care–associated bloodstream infection in the United States and Europe. To our knowledge, this report from the ...

Background: Invasive candidiasis is an increasing problem in neonatal intensive care units worldwide and is an important cause of morbidity, mortality and prolongation of hospital stay. Despite ...

A study in Canada found that nearly half of the solid-organ transplant patients who had Candida bloodstream infections died ...

In recent years, efforts to interrogate established medical practices rooted in sometimes decades-old dogma have led to ...

SAN DIEGO and CAMBRIDGE, England, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate ...

Invasive candidiasis, which in many patients represents a life-threatening condition, is “largely a disease of medical progress,” according to the Guidelines. Risk factors include the use of ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC today announced the peer-reviewed publication of data from the completed ReSTORE phase 3 global clinical trial evaluating REZZAYO ® ...

Please provide your email address to receive an email when new articles are posted on . Among patients with IFI, yeast on donor culture and prolonged length of stay were associated with early IC risk.

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapies designed to save lives and improve the standard of care for patients ...

Credit: Melinta Therapeutics. Rezzayo is supplied as a solid (cake or powder) in a single-dose vial containing 200mg of rezafungin. Rezzayo ™ (rezafungin for injection) is now available for the ...

Publication reaffirms the proven efficacy and safety of rezafungin dosed once-weekly versus a current standard of care echinocandin dosed once-daily Christine Ann Miller, president and chief executive ...

Approval based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and extensive nonclinical development program. REZZAYO ...